58 related articles for article (PubMed ID: 9517377)
1. Ipriflavone as an inhibitor of human cytochrome P450 enzymes.
Monostory K; Vereczkey L; Lévai F; Szatmári I
Br J Pharmacol; 1998 Feb; 123(4):605-10. PubMed ID: 9517377
[TBL] [Abstract][Full Text] [Related]
2. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
Yao HT; Chang YW; Lan SJ; Yeh TK
Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
[TBL] [Abstract][Full Text] [Related]
3. The effect of ipriflavone and its main metabolites on theophylline biotransformation.
Monostory K; Vereczkey L
Eur J Drug Metab Pharmacokinet; 1996; 21(1):61-6. PubMed ID: 8839679
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes.
Kim KA; Lee JS; Park HJ; Kim JW; Kim CJ; Shim IS; Kim NJ; Han SM; Lim S
Life Sci; 2004 Apr; 74(22):2769-79. PubMed ID: 15043991
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
Kim KA; Park JY
Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
[TBL] [Abstract][Full Text] [Related]
6. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
7. Interaction of theophylline and ipriflavone at the cytochrome P450 level.
Monostory K; Vereczkey L
Eur J Drug Metab Pharmacokinet; 1995; 20(1):43-7. PubMed ID: 7588993
[TBL] [Abstract][Full Text] [Related]
8. Validated assays for human cytochrome P450 activities.
Walsky RL; Obach RS
Drug Metab Dispos; 2004 Jun; 32(6):647-60. PubMed ID: 15155557
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of cytostatically active 6-aminobenzo[c]phenanthridines on cytochrome P450 enzymes in human hepatic microsomes.
Zebothsen I; Kunze T; Clement B
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):37-43. PubMed ID: 16867169
[TBL] [Abstract][Full Text] [Related]
10. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate.
Nakajima M; Yoshida R; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 2001 Aug; 29(8):1110-3. PubMed ID: 11454729
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028.
Kim H; Yoon YJ; Kim H; Kang S; Cheon HG; Yoo SE; Shin JG; Liu KH
Toxicol Lett; 2006 Oct; 166(2):105-14. PubMed ID: 16857327
[TBL] [Abstract][Full Text] [Related]
13. Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450.
Ueng YF; Don MJ; Jan WC; Wang SY; Ho LK; Chen CF
Drug Metab Dispos; 2006 May; 34(5):821-7. PubMed ID: 16501007
[TBL] [Abstract][Full Text] [Related]
14. Identification of the human liver microsomal cytochrome P450s involved in the metabolism of N-nitrosodi-n-propylamine.
Teiber JF; Hollenberg PF
Carcinogenesis; 2000 Aug; 21(8):1559-66. PubMed ID: 10910959
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems.
Baranczewski P; Edlund PO; Postlind H
J Pharm Biomed Anal; 2006 Mar; 40(5):1121-30. PubMed ID: 16307862
[TBL] [Abstract][Full Text] [Related]
16. 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol.
Franklin MR; Hathaway LB
Drug Metab Dispos; 2008 Dec; 36(12):2539-46. PubMed ID: 18799803
[TBL] [Abstract][Full Text] [Related]
17. Effects of selective cytochrome P-450 inhibitors on the metabolism of thioridazine. In vitro studies.
Daniel WA; Syrek M; Haduch A
Pol J Pharmacol; 1999; 51(5):435-42. PubMed ID: 10817545
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.
Obach RS; Pablo J; Mash DC
Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
20. [Metabolism of ipriflavone].
Ferenc L; István S
Acta Pharm Hung; 1995 Nov; 65(6):215-8. PubMed ID: 8742628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
